Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR2 | Q92731 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.47 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.45 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | TMPRSS2 | O15393 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | APOB | P04114 | 3/20 | 0.42 |
| ▸ | MTTP | P55157 | 3/20 | 0.42 |
| ▸ | RAF1 | P04049 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1187947 | 0.84 | ESR2 (0.58) | ESR2MAPTJAK2JAK3PTK2 | |
| SCHEMBL6974148 | 0.83 | MTTP (0.59) | ESR2MAPTJAK2JAK3PTK2 | |
| SCHEMBL6496929 | 0.82 | MAPT (0.57) | ESR2MAPTNPC1NAMPT | |
| SCHEMBL31022135 | 0.81 | ESR2 (0.65) | ESR2MAPTJAK2JAK3PTK2 | |
| SCHEMBL14585872 | 0.80 | MTTP (0.54) | JAK2JAK3PTK2ABCB1APOB | |
| SCHEMBL8587342 | 0.79 | APOB (0.52) | ESR2JAK2JAK3PTK2NAMPT | |
| SCHEMBL6531877 | 0.79 | SMN1; SMN2 (0.54) | MAPT | |
| SCHEMBL6487457 | 0.78 | DRD2 (0.47) | ABCB1APOBMTTP | |
| SCHEMBL1188136 | 0.78 | ESR2 (0.55) | ESR2MAPTJAK2JAK3PTK2 | |
| SCHEMBL20704305 | 0.78 | ESR2 (0.63) | ESR2MAPTJAK2JAK3PTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | DAISO CO., LTD. (JP) | 2005-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050038035-A1 | Heterocyclic amide compounds as apolipoprotein b inhibitors | APOB, APOL1, CTRB2 | ESR2 338/4885MAPT 4202/4885JAK2 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.